Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Conditions
Interventions
Ixazomib
Lenalidomide
+1 more
Locations
16
United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Rocky Mountain Cancer Center Rose
Denver, Colorado, United States
Cancer Center of Central Connecticut
Southington, Connecticut, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Mt Sinai Medical Center
Miami Beach, Florida, United States
Start Date
November 22, 2010
Primary Completion Date
March 8, 2013
Completion Date
February 2, 2018
Last Updated
March 14, 2018
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions